Ads
related to: apixaban generic release date
Search results
Results From The WOW.Com Content Network
The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031. [18] In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban. [39] [40] Pfizer reported revenue of US$6.747 billion for Eliquis in 2023. [41]
The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4] Betrixaban (Bevyxxa) was approved in the US in 2017.
Name of the drug Year when the synthesis mechanism was developed Year that was Patented Governmental approval Patented expiry Drug type * 2000: Bevacizumab: 2004: 2024 MA 2001: Valdecoxib: 2016: N/A SM 2001: Etoricoxib: 2016: N/A SM 2003: Alirocumab: 2015: 2035 MA 2006: Linagliptin: 2011 [31] 2031 SM 2007: Apixaban: 2012: 2032 SM 2007 ...
For premium support please call: 800-290-4726 more ways to reach us
The Food and Drug Administration has granted approval for the next-generation anticlotting medication Eliquis, the regulator announced in a news release. The drug, administered in the form of a ...
FDA Accepts Eliquis ® (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery PRINCETON, N.J. & NEW YORK ...
Antistasin, the first discovered naturally occurring direct Xa inhibitor Rivaroxaban, the first synthetic direct Xa inhibitor marketed as a drug Prior to the introduction of direct factor Xa inhibitors, vitamin K antagonists such as warfarin were the only oral anticoagulants for over 60 years, and together with heparin have been the main blood ...
Asundexian efficacy and safety in patients have been evaluated in two clinical trial programs: phase IIb PACIFIC and phase III OCEANIC. [2] In the phase IIb PACIFIC clinical trial programs, asundexian consistently showed no difference in bleeding rate compared with placebo [3] [4] and reduced the risk of bleeding compared with apixaban. [5]